Triple

T20218672
Position Surface form Disambiguated ID Type / Status
Subject Air Test and Evaluation Squadron 21 E495192 entity
Predicate abbreviation P43 FINISHED
Object VX-21
VX-21 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft, weapons, and related systems.
 E1418135 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: VX-21 | Statement: [Air Test and Evaluation Squadron 21, abbreviation, VX-21]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: VX-21
Context triple: [Air Test and Evaluation Squadron 21, abbreviation, VX-21]
  • A. VX-24
    VX-24 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft systems and weapons.
  • B. VX-20
    VX-20 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft and aviation systems.
  • C. VX-31
    VX-31 is a United States Navy air test and evaluation squadron responsible for testing and assessing the performance of naval aircraft and related systems.
  • D. VX-548
    VX-548 is an investigational non-opioid pain medication developed by Vertex Pharmaceuticals that targets NaV1.8 sodium channels to treat acute and chronic pain.
  • E. VX-264
    VX-264 is an investigational therapy being developed by Vertex Pharmaceuticals, likely targeting a serious disease area such as cystic fibrosis or another genetic condition within the company’s clinical pipeline.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: VX-21
Triple: [Air Test and Evaluation Squadron 21, abbreviation, VX-21]
Generated description
VX-21 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft, weapons, and related systems.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: VX-21
Target entity description: VX-21 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft, weapons, and related systems.
  • A. VX-24
    VX-24 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft systems and weapons.
  • B. VX-20
    VX-20 is a U.S. Navy air test and evaluation squadron responsible for testing and assessing naval aircraft and aviation systems.
  • C. VX-31
    VX-31 is a United States Navy air test and evaluation squadron responsible for testing and assessing the performance of naval aircraft and related systems.
  • D. VX-548
    VX-548 is an investigational non-opioid pain medication developed by Vertex Pharmaceuticals that targets NaV1.8 sodium channels to treat acute and chronic pain.
  • E. VX-264
    VX-264 is an investigational therapy being developed by Vertex Pharmaceuticals, likely targeting a serious disease area such as cystic fibrosis or another genetic condition within the company’s clinical pipeline.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69da626cff80819097b530718a7c98b6 completed April 11, 2026, 3:02 p.m.
NER Named-entity recognition batch_69e66edbb67081909c7359ff27205b5f completed April 20, 2026, 6:22 p.m.
NED1 Entity disambiguation (via context triple) batch_6a0843f6580c8190a615d79f15f8143d completed May 16, 2026, 10:16 a.m.
NEDg Description generation batch_6a08449001b4819089cd6399ad76fe49 completed May 16, 2026, 10:18 a.m.
NED2 Entity disambiguation (via description) batch_6a08452b6f9c8190bcaf705698b4a6d2 completed May 16, 2026, 10:21 a.m.
Created at: April 11, 2026, 11:39 p.m.